Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 59 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

482 Biomarker analysis from KESTREL identifies tumor cytotoxicity and immunogenic cell death as predictors of benefit with durvalumab plus tremelimumab in HNSCC

  • Qing Wu1
  • Flavia Michelini2
  • Hung-Ying Lin3
  • Isabella Tilmont4
  • Lara McGrath5
5 affiliations
  1. 1School of Nursing, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  2. 215AstraZeneca, Translational Medicine, Oncology Randd, Waltham, USA
  3. 3AstraZeneca, Waltham, MA, USA
  4. 4Oncology Targeted Discovery, AstraZeneca, Gaithersburg, DC, USA
  5. 5Translational Medicine, Early Oncology & Precision Medicine, AstraZeneca, Waltham, MA, USA
Open at sourcePDFDOICite

Related

  1. A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment
    Saki Sueda, Tomokazu Kawaoka, Yasutoshi Fujii +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  2. Favorable Response to Chemotherapy with Durvalumab Plus Tremelimumab in Two Cases of KRAS G12C-positive Pulmonary Sarcomatoid Carcinoma
    Takeru Ichikawa, Kenichiro Kudo, Yuki Takigawa +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  3. Immune-mediated Myocarditis after Durvalumab/tremelimumab Treatment for Unresectable Hepatocellular Carcinoma
    Shogo Mawatari, Ryu Sasaki, Yasuhiko Nakao +4
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedOncologyJ-STAGE
  4. An Effective Case of Radiofrequency Ablation with the Combination of Durvalumab and Tremelimumab Treatment for Hepatocellular Carcinoma
    Koji Rinka, Kiyohide Kioka, Rika Shioji +16
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  5. An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn – ALICE (PRODIGE89 – UCGI44 – ALICE)
    Octave Letissier, Xavier Adhoute, Boris Campillo-Gimenez +21
    Digestive and Liver DiseasePeer-reviewedCC BY-NC-NDFull textGeneral biologyOncologyHAL

Cite

BibTeXRIS
BibTeX
@article{wu2026biomarker,
  title = {{482 Biomarker analysis from KESTREL identifies tumor cytotoxicity and immunogenic cell death as predictors of benefit with durvalumab plus tremelimumab in HNSCC}},
  author = {Qing Wu and Flavia Michelini and Hung-Ying Lin and Isabella Tilmont and Lara McGrath},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0482},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0482},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 482 Biomarker analysis from KESTREL identifies tumor cytotoxicity and immunogenic cell death as predictors of benefit with durvalumab plus tremelimumab in HNSCC
AU  - Qing Wu
AU  - Flavia Michelini
AU  - Hung-Ying Lin
AU  - Isabella Tilmont
AU  - Lara McGrath
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0482
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0482
SN  - 2051-1426
ER  -